Viking Therapeutics financials at a glance

+ Portfolio

The revenue of Viking Therapeutics is reported as 0 billion Dollars in the fiscal year 2023. The earnings were -0.91 Dollars per share in 2023, which was 26.76 lower than 2021. And about -0.07338 billion Dollars are reported as free cash flow in the financials of Viking Therapeutics 2023. No dividends were paid to the shareholders of the Viking Therapeutics stock NasdaqCM:VKTX in the financial year 2023.

$0.00M

Revenue

$-0.90

Earnings Per Share

0.00%

Gross Margin %

$-48.40M

Free Cash Flow

Revenue

0.00

Earnings Per Share

-0.90

Gross Margin %

0.00

Free Cash Flow

-48.40

Financials

Year	Year	TTM	2022	2021	2020	2019	2018	2017	2016	2015
Rev.	Revenue	N/A	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M	$0.00M
GM %	Gross Margin %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-0.91	$-0.90	$-0.71	$-0.54	$-0.36	$-0.38	$-0.79	$-0.90	$-3.68
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	0	0	0	0	0	0	0	0
Sha.	Shares	N/AM	78.42M	78.36M	74.13M	72.56M	71.99M	35.82M	20.82M	9.68M
OCF	Operating Cash Flow	N/A	$-48.40M	$-47.59M	$-21.78M	$-24.75M	$-18.76M	$0.00M	$0.00M	$0.00M
FCF	Free Cash Flow	N/A	$-48.40M	$-47.59M	$-21.78M	$-31.96M	$-18.76M	$0.00M	$0.00M	$0.00M
FCFS	Free Cash Flow Per Share	$-0.75	$-0.63	$-0.62	$-0.30	$-0.34	$-0.33	$-0.57	$-0.68	$-1.37

Viking Therapeutics financials at a glance

Financials

Discover